ArticleJournal of neuro-oncology2026
Consolidation reduced-dose whole-brain radiation therapy with response-adapted boost in older patients with newly diagnosed primary central nervous system lymphoma.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary central nervous system lymphoma (PCNSL) is relatively common among elderly patients, for whom survival outcomes remain limited and treatment-related decline in functional status is a major concern. This study evaluated the efficacy and functional preservation of reduced-dose whole-brain radiotherapy (WBRT) followed by a response-adapted focal boost as consolidation therapy for PCNSL, with a focus on elderly patients.
methodsWe retrospectively reviewed patients with PCNSL who received consolidation WBRT at a dose of 23.4 Gy after remission-induction therapy with methotrexate, procarbazine, and vincristine at Miyagi Cancer Center between 2015 and 2022. Patients who did not achieve a complete response (CR) after induction therapy received an additional focal boost of 21.6 Gy. Consolidation high-dose cytarabine was generally administered irrespective of response. Median progression-free survival (PFS), median overall survival (OS), and the duration of preserved Karnofsky Performance Status (KPS) scores ≥ 70 were assessed.
resultsSeventy-three patients were included, with a median age of 69 years. The median PFS and OS were 63 months and 90 months, respectively. Multivariate analyses showed that neither advanced age nor an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ≥ 2 significantly affected PFS or OS. At 4 years, the proportions of patients maintaining KPS scores ≥ 70 were 100%, 92%, and 80% in patients aged < 60, 60-69, and ≥ 70 years, respectively.
conclusionsReduced-dose WBRT (23.4 Gy) combined with a response-adapted focal boost was associated with favorable survival and sustained functional preservation, even in elderly or low-PS patients. This strategy may be an effective and feasible consolidation option for frail older patients with PCNSL.
Indexed as
Identifiers
41689681What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.